KalVista Shares Surge as FDA Approves New Drug After Delay

KalVista Pharmaceuticals Inc. shares jumped after the company said it received US Food and Drug Administration approval for its pill for hereditary angioedema, a rare and potentially deadly condition that causes severe swelling throughout the body.